Interleukin-15 dendritic cells harness NK cell cytotoxic effector function in a contact- and IL-15-dependent manner

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Anguille, Sébastien ^a,b   Van Acker, Heleen H ^a   Van Den Bergh, Johan ^a   Willemen, Yannick ^a   Goossens, Herman ^a   Van Tendeloo, Viggo F ^a   Smits, Evelien L ^b,c   Berneman, Zwi N ^a,b   Lion, Eva ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; TUMOR NECROSIS FACTOR ALPHA; CD56 ANTIGEN; CYTOKINE; IL15 PROTEIN, HUMAN; NCAM1 PROTEIN, HUMAN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVATION; CELL CONTACT; CELL SURFACE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MONOCYTE DERIVED DENDRITIC CELL; NATURAL KILLER CELL; NORMAL HUMAN; CELL COMMUNICATION; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; TUMOR CELL LINE;

ANTIGENS, CD56; CELL COMMUNICATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION;

EID: 84929121276     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123340     Document Type: Article

References (68)

1. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012; 62: 309-335. doi: 10.3322/caac.20132 PMID: 22576456
2. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013; 39: 38-48. doi: 10.1016/j.immuni.2013.07.004 PMID: 23890062
3. Anguille S, Smits EL, Lion E, Van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol. 2014; 15: e257-e267. doi: 10.1016/S1470-2045(13)70585-0 PMID: 24872109
4. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. NK cells: key to success of DC-based cancer vaccines?Oncologist. 2012; 17: 1256-1270. doi: 10.1634/theoncologist.2011-0122 PMID: 22907975
5. Van Elssen CH, Oth T, Germeraad WT, Bos GM, Vanderlocht J. Natural killer cells: the secret weapon in dendritic cell vaccination strategies. Clin Cancer Res. 2014; 20: 1095-1103. doi: 10.1158/1078-0432.CCR-13-2302 PMID: 24590885
6. van Beek JJ, Wimmers F, Hato SV, de Vries IJ, Skold AE. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination. Crit Rev Immunol. 2014; 34: 517-536. PMID: 25597314
7. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001; 22: 633-640. PMID: 11698225
8. Ferlazzo G, Morandi B. Cross-talks between natural killer cells and distinct subsets of dendritic cells. Front Immunol. 2014; 5: 159. doi: 10.3389/fimmu.2014.00159 PMID: 24782864
9. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, et al. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol. 2004; 172: 1455-1462. PMID: 14734722
10. Moretta L, Pietra G, Montaldo E, Vacca P, Pende D, Falco M, et al. Human NK cells: from surface receptors to the therapy of leukemias and solid tumors. Front Immunol. 2014; 5: 87. doi: 10.3389/fimmu.2014.00087 PMID: 24639677
11. van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA. Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol. 2003; 171: 5842-5852. PMID: 14634094
12. Adam C, King S, Allgeier T, Braumuller H, Luking C, Mysliwietz J, et al. DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction. Blood. 2005; 106: 338-344. PMID: 15769894
13. Karimi K, Boudreau JE, Fraser K, Liu H, Delanghe J, Gauldie J, et al. Enhanced antitumor immunity elicited by dendritic cell vaccines is a result of their ability to engage both CTL and IFN gamma-producing NK cells. Mol Ther. 2008; 16: 411-418. PMID: 18059374
14. Boudreau JE, Bridle BW, Stephenson KB, Jenkins KM, Brunelliere J, Bramson JL, et al. Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity. Mol Ther. 2009; 17: 1465-1472. doi: 10.1038/mt.2009.95 PMID: 19401673
15. Shimizu K, Fujii S. DC therapy induces long-term NK reactivity to tumors via host DC. Eur J Immunol. 2009; 39: 457-468. doi: 10.1002/eji.200838794 PMID: 19180466
16. Bouwer AL, Saunderson SC, Caldwell FJ, Damani TT, Pelham SJ, Dunn AC, et al. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. J Immunol. 2014; 192: 2514-2521. doi: 10.4049/jimmunol.1202797 PMID: 24477907
17. Homberg N, Adam C, Riedel T, Brenner C, Flatley A, Rocken M, et al. CD40-independent natural killercell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma. Int J Cancer. 2014; 135: 2825-2833. doi: 10.1002/ijc.28932 PMID: 24771135
18. Guo Z, Tilburgs T, Wong B, Strominger JL. Dysfunction of dendritic cells in aged C57BL/6 mice leads to failure of natural killer cell activation and of tumor eradication. Proc Natl Acad Sci U S A. 2014; 111: 14199-14204. doi: 10.1073/pnas.1414780111 PMID: 25225399
19. Osada T, Clay T, Hobeika A, Lyerly HK, Morse MA. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother. 2006; 55: 1122-1131. PMID: 16273350
20. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010; 107: 13824-13829. doi: 10.1073/pnas.1008051107 PMID: 20631300
21. Pellegatta S, Eoli M, Frigerio S, Antozzi C, Bruzzone MG, Cantini G, et al. The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology. 2013; 2: e23401. PMID: 23802079
22. Anguille S, Lion E, Van den Bergh J, Van Acker HH, Willemen Y, Smits EL, et al. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccin Immunother. 2013; 9: 1956-1961. doi: 10.4161/hv.25373 PMID: 23778748
23. Mohamadzadeh M, Berard F, Essert G, Chalouni C, Pulendran B, Davoust J, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med. 2001; 194: 1013-1020. PMID: 11581322
24. Dubsky P, Saito H, Leogier M, Dantin C, Connolly JE, Banchereau J, et al. IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol. 2007; 37: 1678-1690. PMID: 17492620
25. Anguille S, Smits EL, Cools N, Goossens H, Berneman ZN, Van Tendeloo VF. Short-term cultured, in-terleukin- 15 differentiated dendritic cells have potent immunostimulatory properties. J Transl Med. 2009; 7: 109. doi: 10.1186/1479-5876-7-109 PMID: 20021667
26. Harris KM, Fasano A, Mann DL. Monocytes differentiated with IL-15 support Th17 and Th1 responses to wheat gliadin: implications for celiac disease. Clin Immunol. 2010; 135: 430-439. doi: 10.1016/j.clim.2010.01.003 PMID: 20153259
27. Harris KM. Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukoc Biol. 2011; 90: 727-734. doi: 10.1189/jlb.0311132 PMID: 21724805
28. Anguille S, Lion E, Tel J, de Vries IJ, Coudere K, Fromm PD, et al. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One. 2012; 7: e51851. doi: 10.1371/journal.pone.0051851 PMID: 23284789
29. Okada S, Han S, Patel ES, Yang LJ, Chang LJ. STAT3 signaling contributes to the high effector activities of interleukin-15-derived dendritic cells. Immunol Cell Biol. 2015. doi: 10.1038/icb.2014.103
30. Van den Bergh JM, Guerti K, Willemen Y, Lion E, Cools N, Goossens H, et al. HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells. J Cell Mol Med. 2014; 18: 1372-1380. doi: 10.1111/jcmm.12284 PMID: 24979331
31. Roothans D, Smits E, Lion E, Tel J, Anguille S. CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology. 2013; 2: e23037. PMID: 23524451
32. Tel J, Anguille S, Waterborg CE, Smits EL, Figdor CG, de Vries IJ. Tumoricidal activity of human dendritic cells. Trends Immunol. 2014; 35: 38-46. doi: 10.1016/j.it.2013.10.007 PMID: 24262387
33. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. Quantification of IFN-gamma produced by human purified NK cells following tumor cell stimulation: comparison of three IFN-gamma assays. J Immunol Methods. 2009; 350: 89-96. doi: 10.1016/j.jim.2009.08.014 PMID: 19733573
34. Lion E, Anguille S, Berneman ZN, Smits EL, Van Tendeloo VF. Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One. 2011; 6: e20952. doi: 10.1371/journal.pone.0020952 PMID: 21698118
35. Lion E, Smits EL, Berneman ZN, Van Tendeloo VF. Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN-gamma secretion by human NK cells. Leuk Res. 2009; 33: 539-546. doi: 10.1016/j.leukres.2008.08.020 PMID: 18845337
36. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood. 2005; 106: 2252-2258. PMID: 15933055
37. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010; 115: 2167-2176. doi: 10.1182/blood-2009-08-238469 PMID: 19965656
38. Chijioke O, Münz C. Dendritic cell derived cytokines in human natural killer cell differentiation and activation. Front Immunol. 2013; 4: 365. doi: 10.3389/fimmu.2013.00365 PMID: 24273539
39. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity. 2007; 26: 503-517. PMID: 17398124
40. Mortier E, Woo T, Advincula R, Gozalo S, Ma A. IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med. 2008; 205: 1213-1225. doi: 10.1084/jem.20071913 PMID: 18458113
41. Morandi B, Mortara L, Carrega P, Cantoni C, Costa G, Accolla RS, et al. NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs. Int Immunol. 2009; 21: 599-606. doi: 10.1093/intimm/dxp029 PMID: 19325034
42. Robertson MJ, Caligiuri MA, Manley TJ, Levine H, Ritz J. Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol. 1990; 145: 3194-3201. PMID: 1700001
43. Munz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood. 2005; 105: 266-273. PMID: 15331446
44. Bontkes HJ, Kramer D, Ruizendaal JJ, Meijer CJ, Hooijberg E. Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin Immunol. 2008; 127: 375-384. doi: 10.1016/j.clim.2008.02.001 PMID: 18358784
45. Zhang H, Cui Y, Voong N, Sabatino M, Stroncek DF, Morisot S, et al. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. J Immunother. 2011; 34: 187-195. doi: 10.1097/CJI.0b013e31820d2a21 PMID: 21304401
46. Clausen J, Vergeiner B, Enk M, Petzer AL, Gastl G, Gunsilius E. Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells. Immunobiology. 2003; 207: 85-93. PMID: 12675266
47. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene. 2008; 27: 5944-5958. doi: 10.1038/onc.2008.272 PMID: 18836475
48. Lion E, Willemen Y, Berneman ZN, Van Tendeloo VF, Smits EL. Natural killer cell immune escape in acute myeloid leukemia. Leukemia. 2012; 26: 2019-2026. doi: 10.1038/leu.2012.87 PMID: 22446501
49. Vitale M, Della Chiesa M, Carlomagno S, Romagnani C, Thiel A, Moretta L, et al. The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferongamma production upon interaction with dendritic cells. Eur J Immunol. 2004; 34: 1715-1722. PMID: 15162442
50. Ferlazzo G, Pack M, Thomas D, Paludan C, Schmid D, Strowig T, et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc Natl Acad Sci U S A. 2004; 101: 16606-16611. PMID: 15536127
51. Ellis TM, Fisher RI. Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol. 1989; 142: 2949-2954. PMID: 2467946
52. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992; 175: 779-788. PMID: 1346796
53. De Maria A, Bozzano F, Cantoni C, Moretta L. Revisiting human natural killer cell subset function revealed cytolytic CD56(dim)CD16+ NK cells as rapid producers of abundant IFN-gamma on activation. Proc Natl Acad Sci U S A. 2011; 108: 728-732. doi: 10.1073/pnas.1012356108 PMID: 21187373
54. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001; 97: 3146-3151. PMID: 11342442
55. Koka R, Burkett P, Chien M, Chai S, Boone DL, Ma A. Cutting edge: murine dendritic cells require IL-15R alpha to prime NK cells. J Immunol. 2004; 173: 3594-3598. PMID: 15356102
56. Van Elssen CH, Vanderlocht J, Frings PW, Senden-Gijsbers BL, Schnijderberg MC, van Gelder M, et al. Klebsiella pneumoniae-triggered DC recruit human NK cells in a CCR5-dependent manner leading to increased CCL19-responsiveness and activation of NK cells. Eur J Immunol. 2010; 40: 3138-3149. doi: 10.1002/eji.201040496 PMID: 20865789
57. Massa C, Seliger B. Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities. J Immunol. 2013; 190: 3328-3337. doi: 10.4049/jimmunol.1202024 PMID: 23447683
58. Van Elssen CH, Vanderlocht J, Oth T, Senden-Gijsbers BL, Germeraad WT, Bos GM. Inflammation-restraining effects of prostaglandin E2 on natural killer-dendritic cell (NK-DC) interaction are imprinted during DC maturation. Blood. 2011; 118: 2473-2482. doi: 10.1182/blood-2010-09-307835 PMID: 21715307
59. Kobayashi H, Dubois S, Sato N, Sabzevari H, Sakai Y, Waldmann TA, et al. Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance. Blood. 2005; 105: 721-727. PMID: 15367431
60. Zanoni I, Spreafico R, Bodio C, Di Gioia M, Cigni C, Broggi A, et al. IL-15 cis presentation is required for optimal NK cell activation in lipopolysaccharide-mediated inflammatory conditions. Cell Rep. 2013; 4: 1235-1249. doi: 10.1016/j.celrep.2013.08.021 PMID: 24055061
61. Musso T, Calosso L, Zucca M, Millesimo M, Ravarino D, Giovarelli M, et al. Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15. Blood. 1999; 93: 3531-3539. PMID: 10233906
62. Neely GG, Epelman S, Ma LL, Colarusso P, Howlett CJ, Amankwah EK, et al. Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J Immunol. 2004; 172: 4225-4234. PMID: 15034035
63. Romee R, Leong JW, Schneider SE, Sullivan RP, Fehniger TA. IL-15 primes a highly potent anti-leukemia response by CD56bright NK cells. Blood. 2013; 122: 2283-2283. doi: 10.1182/blood-2013-08-516930 PMID: 24072849
64. Fernandez NC, Flament C, Crepineau F, Angevin E, Vivier E, Zitvogel L. Dendritic cells (DC) promote natural killer (NK) cell functions: dynamics of the human DC/NK cell cross talk. Eur Cytokine Netw. 2002; 13: 17-27. PMID: 11956017
65. Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol. 1999; 29: 1656-1666. PMID: 10359120
66. Burt BM, Plitas G, Nguyen HM, Stableford JA, Bamboat ZM, Dematteo RP. Circulating HLA-DR(+) natural killer cells have potent lytic ability and weak antigen-presenting cell function. Hum Immunol. 2008; 69: 469-474. doi: 10.1016/j.humimm.2008.06.009 PMID: 18640163
67. Carrega P, Bonaccorsi I, Di Carlo E, Morandi B, Paul P, Rizzello V, et al. CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph. J Immunol. 2014; 192: 3805-3815. doi: 10.4049/jimmunol.1301889 PMID: 24646734
68. Messaoudene M, Fregni G, Fourmentraux-Neves E, Chanal J, Maubec E, Mazouz-Dorval S, et al. Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res. 2014; 74: 81-92. doi: 10.1158/0008-5472.CAN-13-1303 PMID: 24225017